Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Autozone Inc (AZO) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance

Autozone IncTrade
IDEXX Laboratories, Inc.Trade

Price performance (Past 24H)

Key statistics

Autozone Inc vs IDEXX Laboratories, Inc. — how do they compare? Autozone Inc trades at $3,042 (market cap $49.67B), while IDEXX Laboratories, Inc. trades at $571 (market cap $46.22B). The key difference: Autozone Inc and IDEXX Laboratories, Inc. are close in size by market cap, and IDEXX Laboratories, Inc. is trading nearer its 52-week high, Autozone Inc nearer its low. Which is the better fit depends on your goals.

AZOIDXX
Market Cap
$49.67B$46.22B
Sector
Consumer CyclicalHealth
52-Week High
$4.35K$766.68
52-Week Low
$2.92K$526.44
Enterprise Value
$62.05B$47.12B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Autozone Inc

AutoZone (AZO) trades at $3,045.87, down 0.72% with bearish technical signals despite strong analyst support. The company maintains solid fundamentals with $18.94B revenue and 12.4% net margin, though recent Q3 2025 EPS missed expectations while Q4 2025 and Q1 2026 beat. Operating cash flow remains robust at $3.12B, supporting ongoing expansion initiatives. Recent organizational changes and international growth strategies highlight management's focus on long-term value creation.

AZO presents a compelling value opportunity with 72.7% analyst buy ratings and $3,730 consensus price target representing 22% upside. Key risks include margin compression trends and competitive pressures in auto parts retail. The stock's current technical weakness contrasts with strong institutional conviction, creating potential for recovery if earnings momentum improves.

IDEXX Laboratories, Inc.

IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.

The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Autozone Inc

AutoZone is the premier seller of aftermarket automotive parts, tools, and accessories to do-it-yourself customers in the United States. The company derives an increasing proportion of its sales from domestic commercial customers, although its presence in its home market is still dominated by its do-it-yourself operation, which accounts for nearly 75% of sales in country. AutoZone also has a growing presence in Mexico and Brazil. AutoZone had 6,767 stores in the U.S. (6,051), Mexico (664), and Brazil (52) as of the end of fiscal 2021.

Read more on AZO

About IDEXX Laboratories, Inc.

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.

Read more on IDXX